



INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 4943-103 US	Application Number 10/796,936
		Applicant(s) BOURASSA et al.	
		Filing Date March 10, 2004	Group Art Unit TBD

*EXAMINER	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
<div style="position: relative; height: 100px;"> <div style="position: absolute; top: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; border-radius: 50%; text-align: center; line-height: 100px; font-size: 20px;"> TYPE JC106 SG JUN 17 2004 PATENT & TRADEMARK OFFICE </div> </div>	The Consensus Trial Study Group. "Effects of Enalapril on Mortality in Severe Congestive Heart Failure." N Engl J. Med. 1987; 316: 1429-1435.
	The SOLVD Investigators. "Effect of Enalapril on Mortality and the Development of Heart Failure in Asymptomatic Patients With Reduced Left Ventricular Ejection Fractions" N Engl J. Med. 1992: 327: 685-691.
	Packer M, Poole-Wilson PA, Armstrong PW, et al. "Comparative Effects of Low Doses and High Doses of the Angiotensin Converting Enzyme Inhibitor Lisinopril on Morbidity and Mortality in Chronic Heart Failure." ATLAS study group. Circulation. 1999; 23: 2312-2318.
	Shindler DM, Kostis JB, Yusuf S, et al., "Diabetes Mellitus, A Predictor of Morbidity and Mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry." Am J Cardiol. 1996; 77: 1017-1020.
	Bourassa MG, Gurne O, Bangdiwala SI, et al. "Natural History and Patterns of Current Practice in Heart Failure." J Am Coll Cardiol. 1993; 22(suppl A): 14A-19A.
	The SOLVD Investigators. "Effect of Enalapril on Survival in Patients With Reduced Left Ventricular Ejection Fractions and Congestive Heart Failure." N Engl J Med. 1991; 325: 293-302.
	Lewis EJ, Hunsicker LG, Bain RP, et al. "The Effect of Angiotensin Converting-enzyme Inhibition on Diabetic Nephropathy." N Engl J Med. 1993; 329: 1456-1462.
	The ACE Inhibitors in Diabetic Nephropathy Trialist Group. "Should All Patients With Type 1 Diabetes Mellitus and Microalbuminuria Receive Angiotensin-Converting Enzyme Inhibitor? A meta-analysis of individual patient data. Ann Intern Med. 2001; 134: 370-379.
	Parving HH, Larsen M, Hommel E, et al., "Effect of Antihypertensive Treatment on Blood-Retinal Barrier Permeability to Fluorescein in Hypertensive Type-1 Diabetic Patients with Background Retinopathy." Diabetologia 1989; 32: 440-444.
	The Heart Outcomes Prevention Evaluation Study Investigators. "Effects of an Angiotensin-Converting-Enzyme-Inhibitor, Ramipril, on Cardiovascular Events in High Risk Patients." N Engl J Med. 2000; 342: 145-153.
	Yusuf S, Gerstein H, Hoogwerf B, et al., "Ramipril and the Development of Diabetes." JAMA. 2001; 286: 1882-1485.
<div style="position: relative; height: 100px;"> <div style="position: absolute; bottom: 0; left: 0; width: 100%; height: 100%; border: 1px solid black; text-align: center; line-height: 100px; font-size: 20px;"> SG </div> </div>	The SOLVD Investigators. "Studies of Left Ventricular Dysfunction (SOLVD): Rationale, Design and Methods: Two Trials That Evaluate the Effect of Enalapril in Patients with Reduced Ejection Fraction." Am J Cardiol. 1990;66:315-322.

EXAMINER /Shirley Gembeh/	DATE CONSIDERED 03/06/2007
------------------------------	-------------------------------


*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 4943-103 US	Application Number 10/796,936
		Applicant(s) BOURASSA et al.	
		Filing Date March 10, 2004	Group Art Unit TBD


*EXAMINER INITIAL	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>
	American Diabetes Association. "Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus." Diabetes Care. 1997; 20:1183-201.
	Gress TW, Nieto FJ, Shahar E, et al. "Hypertension and Antihypertensive Therapy as Risk Factors for Type 2 Diabetes Mellitus." N Engl J Med. 2000; 342:905-912.
	Jacob S, Rett K, Wicklmayr M, et al. "Differential Effect of Chronic Treatment With Two Beta-Blocking Agents on Insulin Sensitivity: The Carvedilol-Metoprolol Study." J Hypertens. 1996; 14:489-494.
	Hansson L, Lindholm LH, Niskanen L, et al. "Effects of Angiotensin Converting-Enzyme Inhibition Compared With Conventional Therapy on Cardiovascular Morbidity and Mortality in Hypertension: The Captopril Prevention Project (CAPPP) Randomised Trial." Lancet. 1999;353:611-616.
	Lindholm LH, Ibsen H, Borch-Johnsen K, et al. "Risk of New-Onset Diabetes in the Losartan Intervention for Endpoint Reduction in Hypertension Study." J Hypertens. 2002;20:1879-1886.
	Paolisso G, DeRiu S, Marrazzo G, et al. "Insulin Resistance in Hyperinsulinemia in Patients With Chronic Congestive Heart Failure." Metabolism. 1991;40:972-977.
	Sacks DB, McDonald JM. "The Pathogenesis of Type II Diabetes Mellitus: A Polygenic Disease." Am J Clin Pathol. 1996;105:149-156.
	Uehara M, Kishikawa H, Isami S, et al. "Effect on Insulin Sensitivity of Angiotensin Converting Enzyme Inhibitors with or Without a Sulphydryl Group: Bradykinin May Improve Insulin Resistance in Dogs and Humans." Diabetologia. 1994;37:300-307.
	Yang HY, Erdos EG, Levin Y. "A Dipeptidyl Carboxypeptidase That Converts Angiotensin I and Inactivates Bradykinin." Biochim Biophys Acta. 1970; 214:374-376.
	Tomiyama H, Kushiro T, Abeta H, et al. "Kinins Contribute to the Improvement of Insulin Sensitivity During Treatment with Angiotensin Converting Enzyme Inhibitor." Hypertension. 1994;23:450-455.
	Leighton B, Budohoski L, Lozeman FJ, et al. "The Effect of Prostaglandins E1, E2 and F2a and Indomethacin on the Sensitivity of Glycolysis and Glycogen Synthesis to Insulin in Stipped Soleus Muscles of the Rat." Biochem J. 1985;27:337-340.
 SG	Fryer LGD, Hajdich E, Rencurel F, et al. "Activation of Glucose Transport by AMP-Activated Protein Kinase via Stimulation of Nitric Oxide Synthase." Diabetes. 2000;49:1978-1985.

EXAMINER <div style="text-align: center;">/Shirley Gembeh/</div>	DATE CONSIDERED <div style="text-align: center;">03/06/2007</div>
---	--

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>		Docket Number (Optional) 4943-103 US	Application Number 10/796,936
		Applicant(s) BOURASSA et al.	
		Filing Date March 10, 2004	Group Art Unit TBD
*EXAMINER 	OTHER DOCUMENTS <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>		
	Henriksen EJ, Jacob S, Kinnick TR, et al., "ACE Inhibition and Glucose Transport in Insulin-Resistant Muscle: Roles of Bradykinin and Nitric Oxide." Am J Physiol. 1999;277:R332-R336.		
SG	Balon TW, Nadler JL. "Evidence That Nitric Oxide Increases Glucose Transport in Skeletal Muscle." J Appl Physiol. 1997;82:359-363.		
SG	Shultz TZ, Lewis SB, Westbie DK, et al., "Glucose Delivery: A Modulator of Glucose Uptake in Contracting Skeletal Muscle." Am J Physiol. 1977;2:E514-E518.		
SG	Morel Y, Gadiant A, Keller U, et al., "Insulin Sensitivity in Obese Hypertensive Dyslipidemic Patients Treated with Enalapril or Atenolol." J Cardiovascular Pharmacol. 1995;26:306-311.		
SG	Pollare T, Lithell H, Berne C., "A Comparison of the Effects of Hydrochlorothiazide and Captopril on Glucose and Lipid Metabolism in Patients with Hypertension." N Engl J Med. 1989;321:868-873.		
SG	Carlsson PO, Berne C, Jansson L. "Angiotensin II and the Endocrine Pancreas: Effects on Islet Blood Flow and Insulin Secretion in Rats." Diabetologia. 1998;41:127-133.		
EXAMINER / Shirley Gembeh /		DATE CONSIDERED 03/06/2007	
*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.			

INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i>	Docket Number (Optional) 5197-102 US	Application Number 10/796,936
	Applicant(s) Bourassa, et al.	
	Filing Date March 10, 2004	Group Art Unit 1614



U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

U.S. PATENT APPLICATION PUBLICATIONS

*EXAMINER INITIAL	REF	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	Translation	
							YES	NO

OTHER DOCUMENTS *(Including Author, Title, Date, Pertinent Pages, Etc.)*

SG		Emmanuelle Vermes, et al.; Enalapril Reduces the Incidence of Diabetes in Patients With Chronic Heart Failure; 2003; Circulation; 2003; 107: 1285-1290

EXAMINER <div style="text-align: center;">/Shirley Gembeh/</div>	DATE CONSIDERED <div style="text-align: center;">03/06/2007</div>
---	--

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP Section 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.